Jiudian Pharmaceutical announced on October 8 that it recently received a Drug Registration Certificate issued by the National Medical Products Administration, with certificate number 2026S03671. The drug covered by the certificate is hydrotalcite oral suspension, in the dosage form of an oral suspension, with a specification of 10 ml:1 g, registered as a Category 3 chemical drug and classified as an over-the-counter medicine. The indications include chronic gastritis and gastric discomfort symptoms related to stomach acid. In the first half of 2026, Jiudian Pharmaceutical achieved revenue of 1.287 billion yuan and net profit attributable to the parent company of 160 million yuan.
Hunan Jiudian Pharmaceutical Co LtdJiudian Pharmaceutical received a Drug Registration Certificate from the NMPA for hydrotalcite oral suspension, an approval that expands its product portfolio.
